The application of precision medicine in the diagnosis and treatment of tuberculosis_West China Medical Journal

Authors：

LIU Kun ,  LI Weimin

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

LI Weimin, Email: weimi003@yahoo.com

Keywords：

Precision medicine; Tuberculosis; Diagnosis; Treatment

DOI：

10.7507/1002-0179.201807078

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Precision medicine is a novel medical modality based on genome sequencing, bioinformatics and big data science. The studies regarding tuberculosis always concentrated on the bacteria and host in the setting of precision medicine. This review mainly introduces the application of precision medicine in the diagnosis and treatment of tuberculosis. The limits of the Chinese studies with respect to precision medicine in tuberculosis are also discussed. Moreover, the article predicates its future development.

Citation： LIU Kun, LI Weimin. The application of precision medicine in the diagnosis and treatment of tuberculosis. West China Medical Journal, 2018, 33(8): 926-929. doi: 10.7507/1002-0179.201807078 Copy

1.	Fox JL. Obama catapults patient-empowered precision medicine. Nat Biotechnol, 2015, 33(4): 325.
2.	中華人民共和國國家衛生和計劃生育委員會. 肺結核診斷: WS 288－2017, 2017. http://www.nhfpc.gov.cn/ewebeditor/uploadfile/2017/11/20171128164254246.pdf.
3.	中華醫學會結核病學分會, 結核病病理學診斷專家共識編寫組. 中國結核病病理學診斷專家共識. 中華結核和呼吸雜志, 2017, 40(6): 419-425.
4.	Chakravorty S, Simmons AM, Rowneki M, et al. The new Xpert Mtb/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. MBio, 2017, 8(4): e00812-e00817.
5.	Bhirud P, Joshi A, Hirani N, et al. Rapid laboratory diagnosis of pulmonary tuberculosis. Int J Mycobacteriol, 2017, 6(3): 296-301.
6.	張偉陽, 鐘建平, 楊國彪, 等. LAMP和Xpert Mtb/RIF早期診斷肺結核傳染源的價值比較. 溫州醫科大學學報, 2017(1): 61-63.
7.	Nathavitharana RR, Cudahy PG, Schumacher SG, et al. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J, 2017, 49(1): 1601075.
8.	Meaza A, Kebede A, Yaregal Z, et al. Evaluation of genotype MTBDR plus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infect Dis, 2017, 17(1): 280.
9.	Tang P, Wang X, Shen X, et al. Use of DNA microarray chips for the rapid detection of Mycobacterium tuberculosis resistance to rifampicin and isoniazid. Exp Ther Med, 2017, 13(5): 2332-2338.
10.	Senghore M, Otu J, Witney A, et al. Whole-genome sequencing illuminates the evolution and spread of multidrug-resistant tuberculosis in Southwest Nigeria. PLoS One, 2017, 12(9): e0184510.
11.	Wagh V, Urhekar A, Modi D. Levels of microRNA miR-16 and miR-155 are altered in serum of patients with tuberculosis and associate with responses to therapy. Tuberculosis (Edinb), 2017, 102: 24-30.
12.	Cui JY, Liang HW, Pan XL, et al. Characterization of a novel panel of plasma microRNAs that discriminates between Mycobacterium tuberculosis infection and healthy individuals. PLoS One, 2017, 12(9): e0184113.
13.	Verma R, Pinto SM, Patil AH, et al. Quantitative proteomic and phosphoproteomic analysis of H37Ra and H37Rv strains of Mycobacterium tuberculosis. J Proteome Res, 2017, 16(4): 1632-1645.
14.	Ganmaa D, Munkhzul B, Fawzi W, et al. High-dose vitamin D₃ during tuberculosis treatment in Mongolia. A randomized controlled trial. Am J Respir Crit Care Med, 2017, 196(5): 628-637.
15.	Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol, 2013, 69(5): 1091-1101.

1. Fox JL. Obama catapults patient-empowered precision medicine. Nat Biotechnol, 2015, 33(4): 325.
2. 中華人民共和國國家衛生和計劃生育委員會. 肺結核診斷: WS 288－2017, 2017. http://www.nhfpc.gov.cn/ewebeditor/uploadfile/2017/11/20171128164254246.pdf.
3. 中華醫學會結核病學分會, 結核病病理學診斷專家共識編寫組. 中國結核病病理學診斷專家共識. 中華結核和呼吸雜志, 2017, 40(6): 419-425.
4. Chakravorty S, Simmons AM, Rowneki M, et al. The new Xpert Mtb/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. MBio, 2017, 8(4): e00812-e00817.
5. Bhirud P, Joshi A, Hirani N, et al. Rapid laboratory diagnosis of pulmonary tuberculosis. Int J Mycobacteriol, 2017, 6(3): 296-301.
6. 張偉陽, 鐘建平, 楊國彪, 等. LAMP和Xpert Mtb/RIF早期診斷肺結核傳染源的價值比較. 溫州醫科大學學報, 2017(1): 61-63.
7. Nathavitharana RR, Cudahy PG, Schumacher SG, et al. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J, 2017, 49(1): 1601075.
8. Meaza A, Kebede A, Yaregal Z, et al. Evaluation of genotype MTBDR plus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infect Dis, 2017, 17(1): 280.
9. Tang P, Wang X, Shen X, et al. Use of DNA microarray chips for the rapid detection of Mycobacterium tuberculosis resistance to rifampicin and isoniazid. Exp Ther Med, 2017, 13(5): 2332-2338.
10. Senghore M, Otu J, Witney A, et al. Whole-genome sequencing illuminates the evolution and spread of multidrug-resistant tuberculosis in Southwest Nigeria. PLoS One, 2017, 12(9): e0184510.
11. Wagh V, Urhekar A, Modi D. Levels of microRNA miR-16 and miR-155 are altered in serum of patients with tuberculosis and associate with responses to therapy. Tuberculosis (Edinb), 2017, 102: 24-30.
12. Cui JY, Liang HW, Pan XL, et al. Characterization of a novel panel of plasma microRNAs that discriminates between Mycobacterium tuberculosis infection and healthy individuals. PLoS One, 2017, 12(9): e0184113.
13. Verma R, Pinto SM, Patil AH, et al. Quantitative proteomic and phosphoproteomic analysis of H37Ra and H37Rv strains of Mycobacterium tuberculosis. J Proteome Res, 2017, 16(4): 1632-1645.
14. Ganmaa D, Munkhzul B, Fawzi W, et al. High-dose vitamin D₃ during tuberculosis treatment in Mongolia. A randomized controlled trial. Am J Respir Crit Care Med, 2017, 196(5): 628-637.
15. Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol, 2013, 69(5): 1091-1101.

Previous Article
Precision medicine accelerates tuberculosis control and prevention
Next Article
Current status and future of tuberculosis precision medicine

West China Medical Journal

The application of precision medicine in the diagnosis and treatment of tuberculosis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content